Supplementary Figures S1-S19 from Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma

Le résumé fourni par la source

Figure S1: Gating strategy Flow Panel 1. Supplementary Figure S2: Gating strategy Flow Panel 2 Supplementary Figure S3: Gating strategy Flow Panel 3 Supplementary Figure S4: Gating strategy Flow Panel 3 Supplementary Figure S5: Verification of patient-derived melanoma tumor cell lines using immunohistochemistry staining Supplementary Figure S6: Co-culture controls Supplementary Figure S7: Gating strategy of anti-tumor responses in infusion product T cells following co-culture with their matched autologous tumor cell lines. Supplementary Figure S8: Gating strategy of anti-tumor responses in peripheral blood T cells following co-culture with their matched autologous tumor cell lines. Supplementary Figure S9: Measurement of baseline metabolic tumor volume using whole-body 18FDG PET scans Supplementary Figure S10: Impact of prior anti-PD1 therapy on phenotypic infusion production composition (Part 1) Supplementary Figure S11: Impact of prior anti-PD1 therapy on phenotypic infusion production composition (Part 2) Supplementary Figure S12: Overall composition of the TIL infusion product (TIL-IMP) and its association with progression-free survival Supplementary Figure S13: Expression of IFNy, TNFa, CD107a, and CD137 on CD4+ and CD8+ infusion product T cells after co-culture with their matched autologous tumor cell line Supplementary Figure S14: Anti-tumor responses of CD4+ and CD8+ TIL-IMP T cells Supplementary Figure S15: Impact of estimated baseline MTV on BOR and PFS Supplementary Figure S16: Activation of CD4+ and CD8+ TIL-IMP T cells after stimulation with T cell TransAct or PMA/Ionomycin Supplementary Figure S17: Activation of CD4+ and CD8+ TIL-IMP T cells with T cell TransAct or PMA/Ionomycin Supplementary Figure S18: Expression of MHC Class I (HLA-ABC) and MHC Class II (HLA-DR) on patient-derived TCLs with and without IFNγ pre-stimulation Supplementary Figure S19: PFS curves when stratifying patients by their frequency or absolute number of tumor-reactive CD4+ or CD8+ T cells infused.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.